+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2024

  • ID: 4871667
  • Report
  • December 2019
  • Region: Global
  • 167 Pages
  • Markets and Markets
1 of 6
The Blood Screening Market is Projected to Reach USD 3.3 Billion by 2024 from USD 2.2 Billion in 2019, at a CAGR of 8.7%

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche
  • GFE
  • Merck KGaA
  • MORE

Increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are driving the overall growth of the blood screening market

The blood screening market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%. Growth in this market is driven by the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens. Technological advancements and developing economies are expected to present opportunities for growth for players in the blood screening market. However, the need to reduce blood screening prices is a major factor in challenging market growth.

Nucleic Acid Testing (NAT) segment accounted for the larger share of the blood screening market, by technology, in 2018

The blood screening market, by technology, has been segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment dominates the blood screening market, by technology, primarily due to the increasing number of blood donations and the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies. Based on type, the blood screening market for NAT is segmented into transcription-mediated amplification (TMA) and real-time PCR. Among these, the TMA segment accounts for the larger market share due to the higher sensitivity of this assay.

Blood banks to register the highest growth in the blood screening market during the forecast period

Based on end-users, the blood screening market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing the number of donations worldwide, and growth in government funding to charitable trusts.

North America will continue to dominate the blood screening market during the forecast period

Based on the region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the blood screening market in North America.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%, Tier 2 - 45%, and Tier 3 - 19%
  • By Designation: C-level - 33%, D-level - 40%, and Others - 27%
  • By Region: North America - 39%, Europe - 28%, Asia Pacific - 19%, Latin America- 9% and the Middle East and Africa- 5%

Companies Profiled in the Report
Prominent players in the blood screening market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Ortho Clinical Diagnostics, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

Research Coverage:
This report provides a detailed picture of the global blood screening market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall blood screening market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, opportunities, and trends.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche
  • GFE
  • Merck KGaA
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitation
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.2 Research Design
2.3 Secondary Data
2.3.1 Secondary Source
2.4 Primary Data
2.4.1 Key Data From Primary Sources
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach
2.5.2 Top-Down Approach
2.5.3 Growth Forecast
2.6 Market Breakdown and Data Triangulation
2.7 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Blood Screening: Market Overview
4.2 Asia Pacific: Market Share, By End User & Country (2018)
4.3 Market, By Product & Service, 2019 Vs. 2024 (USD Million)
4.4 Geographical Snapshot of the Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Demand for Donated Blood and Rising Number of Blood Donations
5.2.1.2 Rising Prevalence of Infectious Diseases and Introduction of Newer Pathogens
5.2.2 Opportunities
5.2.2.1 Technological Advancements
5.2.2.2 Emerging Economies
5.2.3 Challenges
5.2.3.1 Need for Reducing Blood Screening Prices

6 Blood Screening Market, By Product & Service
6.1 Introduction
6.2 Reagents & Kits
6.2.1 NAT Reagents & Kits
6.2.1.1 High Sensitivity and Rising use of NAT are Boosting Demand for Related Reagents and Kits
6.2.1.2 Enzymes & Polymerases
6.2.1.3 Standards & Controls
6.2.1.4 Probes & Primers
6.2.1.5 Buffers, Nucleotides, & Solutions
6.2.1.6 Labeling & Detection Reagents
6.2.2 Elisa Reagents & Kits
6.2.2.1 Ease of use and Cost-Effectiveness of Elisa Reagents & Kits Will Drive Market Growth
6.2.2.2 Immunosorbents
6.2.2.3 Controls
6.2.2.4 Conjugates
6.2.2.5 Substrates
6.2.2.6 Sample Diluents and Wash Solutions
6.2.3 Other Reagents
6.2.3.1 Increasing use of Western Blot Tests and Rapid Tests Will Drive the Growth of This Market Segment
6.3 Instruments
6.3.1 Rental Purchase
6.3.1.1 Convenience and Cost-Effectiveness of Renting Instruments has Resulted in Greater End-User Preference
6.3.2 Outright Purchase
6.3.2.1 Availability of Government Support Will Increase the Outright Purchase of Instruments
6.4 Software & Services
6.4.1 Increasing Adoption of Instruments Will Drive the Demand for Related Software and Services

7 Blood Screening Market, By Technology
7.1 Introduction
7.2 Nucleic Acid Testing (NAT)
7.2.1 Transcription-Mediated Amplification
7.2.1.1 Highest Sensitivity of These Assays to Support Market Growth
7.2.2 Real-Time Polymerase Chain Reaction (PCR)
7.2.2.1 Real-Time PCR Procedures Provide More Accurate and Effective Results as Compared to Conventional PCR
7.3 Enzyme-Linked Immunosorbent Assays
7.3.1 Chemiluminescence Immunoassays
7.3.1.1 Clia is Ultrasensitive, Automated, and a Good Alternative to Conventional Methodologies
7.3.2 Fluorescent Immunoassays
7.3.2.1 Rising Demand for Safer and Stable Reagents and the Development of Novel Markers to Support the Growth of This Market Segment
7.3.3 Colorimetric Immunoassays
7.3.3.1 CI Offers Low Sensitivity as It Uses Vulnerable/Limited Signal Amplification Strategies
7.4 Rapid Tests
7.4.1 Rising Awareness About Rapid Tests in Emerging Countries Have Increased the Adoption of These Tests
7.5 Western Blot Assays
7.5.1 Growing Prevalence of TTIS in Developing Countries has Resulted in the Increased Demand for Western Blot Assays
7.6 Next-Generation Sequencing
7.6.1 Ngs is an Emerging Technology in the Market

8 Blood Screening Market, By End User
8.1 Introduction
8.2 Blood Banks
8.2.1 Blood Banks Hold the Largest Share of the Market
8.3 Hospitals
8.3.1 Increasing Number of Surgical Procedures Will Drive the Growth of the Hospitals Segment

9 Blood Screening Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Dominates the Global Market
9.2.2 Canada
9.2.2.1 High Incidence of Sexually Transmitted Diseases in the Country to Support Market Growth
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany is the Largest Market for Blood Screening Technologies in Europe
9.3.2 France
9.3.2.1 Increasing Prevalence of HIV to Support Market Growth
9.3.3 UK
9.3.3.1 Government Support to Prevent Transmission of HIV and Other Infections Will Drive Growth
9.3.4 Italy
9.3.4.1 Italy is Witnessing an Increase in the Number of Blood Donors
9.3.5 Spain
9.3.5.1 Increasing Adoption of NAT Technology Will Support Market Growth
9.3.6 RoE
9.4 Asia Pacific
9.4.1 China
9.4.1.1 China has a High Prevalence of Infectious Diseases
9.4.2 Japan
9.4.2.1 Japan has Witnesses an Increase in the Adoption of Advanced Blood Screening Technologies
9.4.3 India
9.4.3.1 Increasing Number of Road Accidents Will Support Market Growth
9.4.4 Australia
9.4.4.1 Rising Number of Blood Donations Will Propel Market Growth
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Increasing Incidence of Cancer Will Support the Growth of This Market
9.5.2 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Rising Prevalence of Infectious Diseases Will Drive Market Growth in the Region

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis, 2018
10.2.1 Market Share Analysis for NAT Blood Screening, 2018
10.2.2 Market Share Analysis for Total Market, 2018
10.3 Competitive Scenario
10.3.1 Partnerships, Agreements, and Collaborations (2017–2019)
10.3.2 Product Launches (2017–2019)
10.3.3 Expansions (2017–2019)
10.3.4 Acquisitions (2017–2019)
10.4 Competitive Leadership Mapping (2019)
10.4.1 Vendor Inclusion Criteria
10.4.2 Visionary Leaders
10.4.3 Innovators
10.4.4 Dynamic Differentiators
10.4.5 Emerging Companies

11 Company Profiles
11.1 Grifols
11.2 F. Hoffmann-La Roche
11.3 Abbott Laboratories
11.4 BioMérieux
11.5 Bio-Rad Laboratories
11.6 Becton, Dickson and Company
11.7 Danaher Corporation
11.8 Ortho Clinical Diagnostics
11.9 Siemens Healthineers
11.10 Thermo Fisher Scientific
11.11 DiaSorin
11.12 GE Healthcare
11.13 Merck KGaA
11.14 Perkinelmer
11.15 Bio-Techne
11.16 GFE
11.17 Trinity Biotech
11.18 J. Mitra Diagnostics Pvt. Ltd.

12 Appendix
12.1 Discussion Guide
12.2 Knowledge Store: Subscription Portal
12.3 Available Customization
12.4 Related Reports
12.5 Author Details

List of Tables
Table 1 Global Cancer Incidence, 2018 Vs. 2025
Table 2 Blood Screening Market, By Product & Service, 2018–2024 (USD Million)
Table 3 Blood Screening Reagents & Kits Market, By Country, 2018–2024 (USD Million)
Table 4 Blood Screening Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 5 NAT Reagents & Kits Market, By Region, 2018–2024 (USD Million)
Table 6 NAT Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 7 Elisa Reagents & Kits Market, By Region, 2018–2024 (USD Million)
Table 8 Elisa Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 9 Other Reagents & Kits Market, By Region, 2019–2024 (USD Million)
Table 10 Blood Screening Instruments Market, By Region, 2019–2024 (USD Million)
Table 11 Blood Screening Instruments Market, By Mode of Purchase, 2019–2024 (USD Million)
Table 12 Market for Rental Purchase of Blood Screening Instruments, By Country, 2019–2024 (USD Million)
Table 13 Market for Outright Purchase of Blood Screening Instruments, By Country, 2019–2024 (USD Million)
Table 14 Blood Screening Software & Services Market, By Country, 2019–2024 (USD Million)
Table 15 Blood Screening Market, By Technology, 2017–2024 (USD Million)
Table 16 Market for NAT, By Region, 2017–2024 (USD Million)
Table 17 Market for NAT, By Type, 2017–2024 (USD Million)
Table 18 Transcription-Mediated Amplification Market, By Region, 2017–2024 (USD Million)
Table 19 Real-Time PCR Market, By Region, 2017–2024 (USD Million)
Table 20 Market for Elisa, By Region, 2017–2024 (USD Million)
Table 21 Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 22 Chemiluminescence Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 23 Fluorescent Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 24 Colorimetric Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 25 Market for Rapid Tests, By Region, 2017–2024 (USD Million)
Table 26 Blood Screening Market for Western Blot Assays, By Region, 2017–2024 (USD Million)
Table 27 Market for NGS, By Region, 2017–2024 (USD Million)
Table 28 Market, By End User, 2017–2024 (USD Million)
Table 29 Market for Blood Banks, By Region, 2017–2024 (USD Million)
Table 30 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 31 Market, By Region, 2017–2024 (USD Million)
Table 32 North America: Market, By Country, 2017–2024 (USD Million)
Table 33 North America: Blood Screening Market, By Technology, 2017–2024 (USD Million)
Table 34 North America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 35 North America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 36 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 37 North America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 38 North America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 39 North America: Market, By End User, 2017–2024 (USD Million)
Table 40 Incidence of Various Cancers in the Us, 2018 Vs.2025
Table 41 US: Market, By Technology, 2017–2024 (USD Million)
Table 42 US: Blood Screening Market for NAT, By Type, 2017–2024 (USD Million)
Table 43 US: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 44 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 45 US: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 46 US: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 47 US: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 48 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 49 Canada: Market for NAT, By Type, 2017–2024 (USD Million)
Table 50 Canada: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 51 Canada: Market, By Product & Service, 2017–2024 (USD Million)
Table 52 Canada: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 53 Canada: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 54 Canada: Market, By End User, 2017–2024 (USD Million)
Table 55 Europe: Market, By Country, 2017–2024 (USD Million)
Table 56 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 57 Europe: Market for NAT, By Type, 2017–2024 (USD Million)
Table 58 Europe: Blood Screening Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 59 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 60 Europe: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 61 Europe: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 62 Europe: Market, By End User, 2017–2024 (USD Million)
Table 63 Germany: Market, By Technology, 2017–2024 (USD Million)
Table 64 Germany: Market for NAT, By Type, 2017–2024 (USD Million)
Table 65 Germany: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 66 Germany: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 67 Germany: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 68 Germany: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 69 Germany: Market, By End User, 2017–2024 (USD Million)
Table 70 France: Market, By Technology, 2017–2024 (USD Million)
Table 71 France: Market for NAT, By Type, 2017–2024 (USD Million)
Table 72 France: Blood Screening Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 73 France: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 74 France: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 75 France: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 76 France: Market, By End User, 2017–2024 (USD Million)
Table 77 UK: Market, By Technology, 2017–2024 (USD Million)
Table 78 UK: Market for NAT, By Type, 2017–2024 (USD Million)
Table 79 UK: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 80 UK: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 81 UK: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 82 UK: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 83 UK: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 84 Italy: Market, By Technology, 2017–2024 (USD Million)
Table 85 Italy: Market for NAT, By Type, 2017–2024 (USD Million)
Table 86 Italy: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 87 Italy: Market, By Product & Service, 2017–2024 (USD Million)
Table 88 Italy: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 89 Italy: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 90 Italy: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 91 Spain: Market, By Technology, 2017–2024 (USD Million)
Table 92 Spain: Market for NAT, By Type, 2017–2024 (USD Million)
Table 93 Spain: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 94 Spain: Market, By Product & Service, 2017–2024 (USD Million)
Table 95 Spain: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 96 Spain: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 97 Spain: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 98 RoE: Market, By Technology, 2017–2024 (USD Million)
Table 99 RoE: Market for NAT, By Type, 2017–2024 (USD Million)
Table 100 RoE: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 101 RoE: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 102 RoE: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 103 RoE: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 104 RoE: Market, By End User, 2017–2024 (USD Million)
Table 105 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 106 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 107 Asia Pacific: Market for NAT, By Type, 2017–2024 (USD Million)
Table 108 Asia Pacific: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 109 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 110 Asia Pacific: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 111 Asia Pacific: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 112 Asia Pacific: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 113 China: Market, By Technology, 2017–2024 (USD Million)
Table 114 China: Market for NAT, By Type, 2017–2024 (USD Million)
Table 115 China: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 116 China: Market, By Product & Service, 2017–2024 (USD Million)
Table 117 China: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 118 China: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 119 China: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 120 Japan: Market, By Technology, 2017–2024 (USD Million)
Table 121 Japan: Market for NAT, By Type, 2017–2024 (USD Million)
Table 122 Japan: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 123 Japan: Market, By Product & Service, 2017–2024 (USD Million)
Table 124 Japan: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 125 Japan: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 126 Japan: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 127 India: Market, By Technology, 2017–2024 (USD Million)
Table 128 India: Market for NAT, By Type, 2017–2024 (USD Million)
Table 129 India: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 130 India: Market, By Product & Service, 2017–2024 (USD Million)
Table 131 India: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 132 India: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 133 India: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 134 Australia: Market, By Technology, 2017–2024 (USD Million)
Table 135 Australia: Market for NAT, By Type, 2017–2024 (USD Million)
Table 136 Australia: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 137 Australia: Market, By Product & Service, 2017–2024 (USD Million)
Table 138 Australia: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 139 Australia: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 140 Australia: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 141 RoAPAC: Market, By Technology, 2017–2024 (USD Million)
Table 142 RoAPAC: Market for NAT, By Type, 2017–2024 (USD Million)
Table 143 RoAPAC: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 144 RoAPAC: Market, By Product & Service, 2017–2024 (USD Million)
Table 145 RoAPAC: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 146 RoAPAC: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 147 RoAPAC: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 148 Latin America: Market, By Country, 2017–2024 (USD Million)
Table 149 Latin America: Market, By Technology, 2017–2024 (USD Million)
Table 150 Latin America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 151 Latin America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 152 Latin America: Market, By Product & Service, 2017–2024 (USD Million)
Table 153 Latin America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 154 Latin America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 155 Latin America: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 156 Incidence of Various Cancers in Brazil, 2018 Vs.2025
Table 157 Brazil: Market, By Technology, 2017–2024 (USD Million)
Table 158 Brazil: Market for NAT, By Type, 2017–2024 (USD Million)
Table 159 Brazil: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 160 Brazil: Market, By Product & Service, 2017–2024 (USD Million)
Table 161 Brazil: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 162 Brazil: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 163 Brazil: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 164 Rest of Latin America: Market, By Technology, 2017–2024 (USD Million)
Table 165 Rest of Latin America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 166 Rest of Latin America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 167 Rest of Latin America: Market, By Product & Service, 2017–2024 (USD Million)
Table 168 Rest of Latin America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 169 Rest of Latin America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 170 Rest of Latin America: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 171 MEA: Market, By Technology, 2017–2024 (USD Million)
Table 172 MEA: Market for NAT, By Type, 2017–2024 (USD Million)
Table 173 MEA: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 174 MEA: Market, By Product & Service, 2017–2024 (USD Million)
Table 175 MEA: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 176 MEA: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 177 MEA: Market, By End User, 2017–2024 (USD Million)

List of Figures
Figure 1 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Data Triangulation Methodology
Figure 5 Blood Screening Market, By Product & Service, 2019 Vs. 2024 (USD Billion)
Figure 6 Market, By Technology, 2019 Vs. 2024 (USD Billion)
Figure 7 Market, By End User, 2019 Vs. 2024 (USD Billion)
Figure 8 Geographic Outlook: Market
Figure 9 Increasing Prevalence of Chronic & Infectious Diseases to Drive Market Growth
Figure 10 Blood Banks Accounted for the Largest Share in the Asia Pacific in 2018
Figure 11 Reagents and Kits Sub Segment Dominates the Blood Screening Products Market
Figure 12 China to Register the Highest CAGR During the Forecast Period
Figure 13 Rise in HIV-Affected Patient Population, 2000–2018
Figure 14 Reagents & Kits Segment is Expected to Hold the Largest Share of the Market During the Forecast Period
Figure 15 NAT Segment Will Continue to Dominate the Blood Screening Market in 2024
Figure 16 Blood Banks Will Continue to Dominate the Market During the Forecast Period
Figure 17 North America: Market Snapshot
Figure 18 Asia Pacific: Market Snapshot
Figure 19 Key Players Adopted Organic as Well as Inorganic Growth Strategies Between 2016 and 2019
Figure 20 Market Evolution Framework
Figure 21 NAT Blood Screening Market Share Analysis, By Key Player, 2018
Figure 22 Market Share Analysis, By Key Player, 2018
Figure 23 Competitive Leadership Mapping
Figure 24 Grifols: Company Snapshot (2018)
Figure 25 F. Hoffman-La Roche: Company Snapshot (2018)
Figure 26 Abbott Laboratories: Company Snapshot (2018)
Figure 27 BioMérieux: Company Snapshot (2018)
Figure 28 Bio-Rad Laboratories: Company Snapshot (2018)
Figure 29 Becton, Dickson and Company: Company Snapshot (2018)
Figure 30 Danaher Corporation: Company Snapshot (2018)
Figure 31 Siemens Healthineers: Company Snapshot (2018)
Figure 32 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 33 DiaSorin: Company Snapshot (2018)
Figure 34 General Electric: Company Snapshot (2018)
Figure 35 Merck KGaA: Company Snapshot (2018)
Figure 36 Perkinelmer: Company Snapshot (2018)
Figure 37 Bio-Techne Corporation: Company Snapshot (2018)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Abbott Laboratories
  • Becton, Dickson and Company
  • Bio-Rad Laboratories
  • Bio-Techne
  • BioMérieux
  • Danaher Corporation
  • DiaSorin
  • F. Hoffmann-La Roche
  • GE Healthcare
  • GFE
  • Grifols
  • J. Mitra Diagnostics Pvt. Ltd.
  • Merck KGaA
  • Ortho Clinical Diagnostics
  • Perkinelmer
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Trinity Biotech
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll